What is LOPJLB’s current signal on ERAS?

LOPJLB’s latest quantitative signal on Erasca, Inc. (ERAS) is SELL in a RECOVERY regime. Signals are updated daily.

What market regime is ERAS in?

Erasca, Inc. (ERAS) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does Erasca, Inc. (ERAS) do?

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, a…

Where is Erasca, Inc. based / listed?

Erasca, Inc. is based in US, listed on NASDAQ.

Erasca, Inc. (ERAS)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$16.03+3.69%Close

SELLRECOVERY · day 8

[SCORES & PROFILE]

FUND: 16
VALUE: 8
GROWTH: 45
GARP: 6
TYPE: Balanced

Composite of Value · Growth · GARP

ROIC-48.3%

REV YoY-

ROE-80.4%

EPS YoY-

ROA-66.0%

GROSS

NET

[VALUATION]

P/E TTM-15.05

P/E FWD-

SECTOR PE20.47

INDUSTRY PE13.95

P/B12.30

P/FCF-

EV/EBITDA-17.47

EV/EBIT-

PEG-

FCF YIELD-

RISK

INT COV-

D/E12.36

ALTMAN Z-

CURR RATIO8.29

ND/EBITDA-

BETA0.62

Erasca, Inc. (ERAS)

Key stats

Industry peers

Prediction markets

FUNDAMENTALS

Company news